(Q39935539)

15 September 2017

title

Exploiting the tumor microenvironment in the development of targeted cancer gene therapy (English)

1 reference

15 September 2017

0 references

1 reference

G J Dougherty

1

1 reference

15 September 2017

S T Dougherty

series ordinal

2

1 reference

15 September 2017

publication date

26 September 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

16

1 reference

15 September 2017

issue

3

1 reference

15 September 2017

page(s)

279-290

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2008.72

15 September 2017

exact match

0 references

cites work

Adenoviral vectors: systemic delivery and tumor targeting

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Cancer gene therapy: an awkward adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Cell and tissue targeting of nucleic acids for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Gene therapy vector design strategies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Gene therapy: designer promoters for tumour targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Transductional targeting of adenovirus vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Alternative splicing as a novel of means of regulating the expression of therapeutic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Vascular-targeted cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Hypoxia: a key regulator of angiogenesis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Vascular integration of endothelial progenitors during multistep tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Microenvironmental and cellular consequences of altered blood flow in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

VEGF as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Functional VEGF and VEGF receptors are expressed in human medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Angiogenesis: an organizing principle for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Molecular and cellular regulators of cancer angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Tumoral angiogenesis: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Ceramide enables fas to cap and kill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Daxx enhances Fas-mediated apoptosis in a murine pro-B cell line, BAF3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

cMet and Fas receptor interaction inhibits death-inducing signaling complex formation in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

CD95 rapidly clusters in cells of diverse origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Swapping between Fas and granulocyte colony-stimulating factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Angiogenesis in bladder cancer--prognostic marker and target for future therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Expression of Protein Tyrosine Kinases in Islet Cells: Possible Role of the Flk-1 Receptor forβ-Cell Maturation from Duct Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Pathways for aberrant angiogenesis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

VEGF receptor expression and signaling in human bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Therapeutic anti-VEGF antibodies

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Biosafety of in vivo adenovirus-p53 intravesical administration in mice

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: Flt-1 and VEGF expression in renal mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.72

7 January 2021

Identifiers

DOI

10.1038/CGT.2008.72

1 reference

15 September 2017

1 reference